SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hollenberg, N. K
Right arrow Articles by Sever, P. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollenberg, N. K
Right arrow Articles by Sever, P. S
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Editorial

The past, present and future of hypertension management: a potential role for AT1-receptor antagonists

Norman K Hollenberg

Department of Radiology and Medicine, Brigham and Women's Hospital Boston, Massachusetts, USA

Peter S Sever

Department of Clinical Pharmacology, Imperial College School of Medicine, St Mary's Hospital, London, UK

The benefits of effective antihypertensive treatment were established at least 40 years ago, but despite the availability of more reliable and better-tolerated antihypertensive drugs, the control of blood pressure remains poor in most patients. Long-term antihypertensive efficacy requires treatment that combines reliable 24-hour reduction of blood pressure with good tolerability to facilitate patient compliance.Treatment should also protect against target-organ damage.As the majority of negative cardiovascular effects of angiotensin II are mediated through the angiotensin II type 1 (AT1) receptor, specific blockade of this receptor is a rational approach for achieving these ideals. Several AT1-receptor blockers have been developed that combine antihypertensive efficacy and placebo-like tolerability — the latter being unique in the history of antihypertensive therapy. In experimental animals these drugs prevent or reverse target organ damage in the heart, the vasculature and the kidney. Ongoing large-scale outcome studies are now underway to establish the benefits of AT1-receptor blockade beyond blood pressure control.

Key Words: hypertension • renin-angiotensin-aldosterone system • angiotensin receptor antagonists

References

  • Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 212: 1028-1034.
  • Health Survey for England '96.Volume 1. London: The Stationery Office, 1998.
  • The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.[Abstract/Free Full Text]
  • Dickinson CJ Neurogenic hypertension: a synthesis and review. London: Chapman and Hall, 1991.
  • MacMahon S., Rodgers A. The effects of antihypertensive treatment on vascular disease: Reappraisal of the evidence in 1994 J Vasc Med Biol 1993; 4: 265-271.
  • Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg.JAMA 1970; 213: 1143-1152.[Abstract/Free Full Text]
  • Medical Research Council Working Party. MRC trial on treatment of hypertension: principal results. BMJ 1985; 291: 97-104.[Abstract/Free Full Text]
  • Dahlöf B., Lindeholm LH, Hansson L. et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1284.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255-3264.[Abstract/Free Full Text]
  • Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-1892.[Abstract/Free Full Text]
  • Staessen JA, Fagard R., Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients. New Engl J Med 2000; 342: 145-153.[Abstract/Free Full Text]
  • Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-183.[Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Zanchetti A., Carruthers G. et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Taylor Nelson Healthcare: Copyright Cardiomonitor®, 1992.
  • Burt V.-L,Wheiton P., Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-313.[Abstract/Free Full Text]
  • Bennett SA, Magnus P. Trends in cardiovascular risk factors in Australia. Results from the National Heart Foundation's Risk Factor Prevalence Study, 1980-1989. Med J Australia 1994;161:519-527.[Medline] [Order article via Infotrieve]
  • Hosie J., Wiklund I. Managing hypertension in general practice: Can we do better? J Hum Hypertens 1995; 9: 515-518.
  • Isles CG, Walker LM, Beevers GD et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4: 141-156.[Web of Science][Medline] [Order article via Infotrieve]
  • Jones JK, Gorkin L., Lian JF et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293-295.[Abstract/Free Full Text]
  • Juilleret L., Nussberger J., Ménard J. et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990;16:564-572.[Abstract/Free Full Text]
  • Urata H., Nishimura H., Ganten D. Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens 1996;9:277-284.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ménard J., Chatellier G.,Azizi M. Do we need angiotensin II antagonists to treat hypertensive patients? J Hum Hypertens 1997;11(suppl 2):S1-7.[CrossRef][Medline] [Order article via Infotrieve]
  • Israili ZH, Hall WD Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-242.[Abstract/Free Full Text]
  • Sunman W., Sever PS Non-angiotensin effects of angiotensin converting enzyme inhibitors. Clin Sci 1993; 85: 661-670.[Web of Science][Medline] [Order article via Infotrieve]
  • Booz GW, Baker KM Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996; 28: 635-640.[Abstract/Free Full Text]
  • Ford WR, Clanachan AS, Jugdutt BI Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996; 94: 3087-3089.[Abstract/Free Full Text]
  • Garcha RS, Sever PS, Hughes AD Action of AT1-receptor antagonists on angiotesin II-induced tone in human isolated subcutaneous resistance arteries. Br J Pharmacol 1999;127(8):1876-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Morsing P., Adler G., Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-1413.[Abstract/Free Full Text]
  • Vanderheyden PML, Fierens FLP, de Backer JP et al. Distinction between surmountable and insurmountable selective AT1-receptor antagonists by use of CHO-K11 cells expressing human angiotensin II AT1-receptors. Br J Pharmacol 1999; 126: 1057-1065.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • ChiuAT, Mccall DE, Price WA,Wong PC, Carini DJ, Duncia JV,Wexler RR,Yoo SE, Johnson AL, & Timmermans PB Nonpeptide angiotensin II receptor antagonists.VII. Cellular and biochemical pharmacology of DUP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.[Abstract/Free Full Text]
  • Corriu C., Bernard S., Schott C. & Stoclet JC Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 1995; 26: 688-692.[Web of Science][Medline] [Order article via Infotrieve]
  • Noda M., Shibouta Y., Inada Y., Ojima M., Wada T., Sanada T., Kubo K., Kohara Y., Naka T. & Nishikawa K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993; 46: 311-318.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chiu,AT Mccall D.,Aldrich PE & Timmermans PB [3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype. Biochem Biophys Res Commun 1990;172:1195-202.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chiu AT, Mccall DE, Ardecky RJ, Duncia JV, Nguyen TT & Timmermans PB Angiotensin II receptor subtypes and their selective nonpeptide ligands. Receptor 1990;1:33-40.[Medline] [Order article via Infotrieve]
  • Wong PC, Hart SD, Zaspel AM, Chiu AT,Ardecky RJ, Smith RD & Timmermans PB Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DUP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther 1990; 255: 584-592.[Abstract/Free Full Text]
  • Ojima M., InadaY., Shibouta Y., Wada T., Sanada T., Kubo K.& Nishikawa K. Candesartan (CV-11974) dissociates slowly from the angiotensin AT -receptor. Eur J Pharmacol 1997; 319: 137-146.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Pressure 1998; 7: 53-59.[CrossRef][Medline] [Order article via Infotrieve]
  • Kassler-Taub K., Littlejohn T., Elliott W. et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11(4, part 1): 445-453.
  • Gradman AH, Arcuri KE, Goldberg AI et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.[Abstract/Free Full Text]
  • Lacourcière Y.,Asmar R., on behalf of the CHAMP study group. Comparison of the impact of missed doses of candesartan and losartan in ambulatory hypertensive patients. Am J Hypertens 1999;12(4,part 2): 143A.
  • Inada Y., Wada T., Ojima M. et al. Protective effects of candesartan cilexetil (TCV116) on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997;19:1079-1099.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mitsunami K., Inoue S., Maeda K. et al.Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12: 469-474.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl 1998;16:S23-S29.[CrossRef][Medline] [Order article via Infotrieve]
  • Tedesco MA, Ratti G.,Aquino D. et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12: 505-510.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Thurmann PA, Kenedi P., Schmidt A. et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.[Abstract/Free Full Text]
  • Fridman K., Andersson OK, Wysocki M., Friberg P. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol1998; 54: 497-501.1.
  • Fridman K.,Wysocki M., Friberg P.,Andersson O. Long-term effects of candesartan cilexetil on the systemic and renal haemodynamics in moderately hypertensive patients. Am J Hypertens 1998;11(4,part 2): 77A.
  • Forsblom C., Trenkwalder P., Dahl K. et al. Candesartan cilexetil, a novel angiotensin II antagonist reduces microalbuminuria in patients with type II diabetes mellitus and mild hypertension. Am J Hypertens 1997; 10(4, part 2): 86A.
  • Dahlöf B., Devereux RB, Julius S. et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. Hypertension 1998; 32: 989-997.[Abstract/Free Full Text]
  • Mann J., Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998; 7: 176-183.[CrossRef][Medline] [Order article via Infotrieve]
  • Hansson L., Lithell H., Skoog I. et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Pressure 1999; 8: 177-183.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Burnier M., Brunner HR Antagonistes des récepteurs AT1 de l'angiotensine II: développement clinique et perspectives futures. [Angiotensin II AT1-receptor antagonists: clinical development and future perspectives.] Therapie 1998; 53: 279-284. (French).[Web of Science][Medline] [Order article via Infotrieve]
  • Ritz E., Rychlik I., Miltenberger-Miltenyi G. Optimizing antihypertensive therapy in patients with diabetic nephropathy. J Hypertens Suppl 1998; 16(7): S17-S22.

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 1, 5-10 (2000)
DOI: 10.3317/jraas.2000.011
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hollenberg, N. K
Right arrow Articles by Sever, P. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollenberg, N. K
Right arrow Articles by Sever, P. S
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement